News

BMJ2d
Six months open label trial of leflunomide in active ankylosing spondylitis
Objective: To examine the potential therapeutic effects of leflunomide in patients with active AS in an open label study. Patients and methods: Twenty patients with AS fulfilling the 1984 modified New ...
BMJ2d
Open label trial of anakinra in active ankylosing spondylitis over 24 weeks
Objective: To examine the therapeutic effect of the interleukin 1 (IL1) receptor antagonist anakinra in ankylosing spondylitis in an open label trial. Methods: Anakinra (100 mg) was given ...
BMJ2d
High-resolution MRI assessment of dactylitis in psoriatic arthritis shows flexor tendon pulley and sheath-related enthesitis
Objective Dactylitis is a hallmark of psoriatic arthritis (PsA) where flexor tenosynovitis is common. This study explored the microanatomical basis of dactylitis using high-resolution MRI (hrMRI) to ...
BMJ5d
Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis
1 Department of Rheumatology, Medisch Spectrum Twente, Enschede, The Netherlands 2 Department of Rheumatology, University Medical Centre Nijmegen, The Netherlands 3 Department of Rheumatology, Leiden ...
BMJ5d
CCL2/CCR2, but not CCL5/CCR5, mediates monocyte recruitment, inflammation and cartilage destruction in osteoarthritis
5 Department of Orthopedic Surgery and Department of Bioengineering, Stanford University, Stanford, California, USA Correspondence to Dr William H Robinson, Division of Immunology and Rheumatology, ...
BMJ5d
Lack of EULAR/ERA-EDTA response at 1 year predicts poor long-term renal outcome in patients with lupus nephritis
Objectives Short-term predictive endpoints of chronic kidney disease (CKD) are needed in lupus nephritis (LN). We tested response to therapy at 1 year. Results We studied 381 patients (90.5% ...
BMJ7d
A disease activity score for polymyalgia rheumatica
Objective: To develop a composite score for measurement of disease activity in polymyalgia rheumatica (PMR) and assess its internal and external validity. Methods: A PMR activity score (AS) was ...
BMJ7d
Clinical and ultrasonographic predictors of joint replacement for knee osteoarthritis: results from a large, 3-year, prospective EULAR study
11 Paris-Descartes University, Medicine Faculty, UPRES-EA 4058 & APHP, Cochin Hospital, Rheumatology B Department, Paris, France Correspondence to Professor Maxime Dougados, Paris-Descartes University ...
BMJ8d
Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA)
19 Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, and 2nd Department of Medicine, Hietzing Hospital, Vienna, Austria 20 Department of Rheumatology, Seoul National ...
BMJ12d
Metagenome-wide association study revealed disease-specific landscape of the gut microbiome of systemic lupus erythematosus in Japanese
Correspondence to Dr Yukinori Okada, Department of Statistical Genetics, Osaka University Graduate School of Medicine, Suita 565-0871, Japan; yokada{at}sg.med.osaka-u.ac.jp Objective Alteration of the ...
BMJ19d
2019 update of the EULAR recommendations for the management of systemic lupus erythematosus
Correspondence to Dr Antonis Fanouriakis, Rheumatology and Clinical Immunology Unit, “Attikon” University Hospital, Athens 12462, Greece; afanour{at}med.uoa.gr Our objective was to update the EULAR ...
BMJ19d
Short-term dose and duration-dependent glucocorticoid risk for cardiovascular events in glucocorticoid-naive patients with rheumatoid arthritis
Objectives Rheumatoid arthritis (RA), along with glucocorticoid use, is associated with cardiovascular disease. Cardiovascular safety of glucocorticoids in RA is controversial and may be related to ...